A46G and C79G polymorphisms in the 尾2-adrenergic receptor gene (ADRB2) and essential hypertension risk: a meta-analysis AbstractNo consensus has been reached on the association between the 尾2-adrenergic receptor polymorphisms A46G and C79G and essential hypertension risk. We performed a meta-analysis to confirm the possible association. After reviewing 303 reports in PubMed and 359 reports in Embase, we included in our meta-analysis 18 articles (20 studies) that met our inclusion criteria. The fixed-effects model and the random-effects model were applied for dichotomous outcomes to combine the results of the individual studies. There was no statistical association between A46G and hypertension risk in all subjects, Asians or Caucasians. However, an association was observed in the dominant genetic model (AA vs. (AG+GG)) (P=0.04, odds ratio (OR)=1.38, 95% confidence interval (CI) 1.01鈥?.87, Pheterogeneity=0.98, fixed-effects model) in the subgroup of mixed Africans. No overall statistical association could be found between C79G and hypertension risk or any ethnic subgroup. In the research conducted on severe hypertension (systolic blood pressure 猢?/span>160鈥塵m鈥塇g and/or diastolic blood pressure 猢?/span>95鈥塵m鈥塇g hypertensive population), significant association was found in the dominant genetic model (CC vs. (CG+GG)) (P=0.04, OR=1.38, 95% CI 1.02鈥?.86, Pheterogeneity=0.03, random-effects model), and there was also a borderline significance between the C79 allele and severe hypertension (P=0.05, OR=1.26, 95% CI 1.00鈥?.57, Pheterogeneity=0.04, random-effects model). No association could be found in this study between the two polymorphisms and stage 2 hypertension. More studies stratified for different ethnicities and different stages of hypertension should be performed in the future. IntroductionEssential hypertension is an escalating problem in modern society. It is widely considered a complex genetic trait caused by multiple susceptibility genes, the effects of which are modulated by gene鈥揺nvironment and gene鈥揼ene interactions.1 As a consequence, many gene polymorphisms have been assessed as candidate determinants of the risk of hypertension.At the molecular level, the role of the 尾2-adrenergic receptor, ADRB2, in hypertension has been extensively evaluated, paying particular attention to the rs1042713 (Arg16Gly, A46G) and rs1042714 (Gln27Glu, C79G) single-nucleotide polymorphisms on chromosome 5q31 to 32.2 In vitro, compared with wild-type A46, the G46 allele displayed normal agonist binding and functional coupling to Gs, resulting in the stimulation of adenylyl cyclase activity. Similar results were found in the comparison between the C79 and G79 alleles.3 In clinical and epidemiologic populations, some studies have indicated that the A46G polymorphism4, 5, 6, 7, 8, 9, 10 as well as the C79G polymorphism5, 6, 8, 10, 11 in the ADRB2 gene is associated with essential hypertension (or BP level). Other studies have been unable to replicate these findings.12, 13, 14, 15, 16, 17, 18, 19, 20 Therefore, in spite of the large number of previous reports about the association between these two polymorphisms and hypertension, the conclusion remains unclear. To clarify the effect of A46G and C79G polymorphisms on the risk of hypertension, we conducted a meta-analysis from all eligible case鈥揷ontrol studies published to date.Materials and methodsIdentification and eligibility of relevant studiesTo identify all the studies that examined the association of A46G and C79G polymorphisms with hypertension, we conducted a computerized literature search of PubMed and Embase databases (before January 2010) using the following keywords and subject terms: 鈥榓drenergic鈥?or 鈥榓drenoceptor鈥? 鈥榩olymorphism鈥?and 鈥榟ypertension鈥? References of retrieved articles were also screened. If an article reported results on different ethnic sub-populations, each sub-population was treated as a separate study in our meta-analysis. Studies included in the meta-analysis had to meet all the following criteria: (i) use of an unrelated case鈥揷ontrol design, (ii) available genotype frequency, (iii) the genotype distribution of the control population must be in Hardy鈥揥einberg equilibrium (HWE) and (iv) hypertension defined as systolic blood pressure (SBP)猢?/span>140鈥塵m鈥塇g and/or diastolic blood pressure (DBP)猢?/span>90鈥塵m鈥塇g and/or treatment with antihypertensive medication; stage 2 hypertension was defined as SBP猢?/span>160鈥塵m鈥塇g and/or DBP猢?/span>100鈥塵m鈥塇g.21, 22 To minimize bias in the selection of studies, two observers independently extracted the information from each study. Disagreements were resolved in consensus by discussion between the authors. If a paper did not provide relevant data, or if the data provided were not sufficient, we contacted corresponding or original authors by e-mail in order to obtain the raw data.Data extractionData were collected on the genotype of A46G and C79G according to ethnicity. First author, year of publication, diagnostic standards of each study, number of cases and controls, number and frequency of genotypes, and allele frequency of both polymorphisms in cases and controls are described in Tables 1, 2a and b.Table 1 Characteristics of eligible studies considered in the meta-analysisFull size tableTable 2a Characteristics of studies and the distribution of ADRB2 A46G genotypes and alleles among hypertension of cases and controls in the meta-analysisFull size tableTable 2b Characteristics of studies and the distribution of ADRB2 C79G genotypes and alleles among hypertension of cases and controls in the meta-analysisFull size tableStatistical analysisThe strength of the association of A46G and C79G with hypertension was measured by an odds ratio (OR) corresponding to a 95% confidence interval (CI), which was calculated according to the method used by Woolf.23 We examined the association between allele A of A46G and hypertension, as well as the dominant genetic model (AA vs. GG + AG), the recessive genetic model (AA + AG vs. GG) and homozygote comparison (AA vs. GG). The same method was applied to analysis of the C79G polymorphism. In our study, two models of meta-analysis were applied for dichotomous outcomes in ReviewManager 4.2 software (The Cochrane Collaboration, Oxford, UK): the fixed-effects model and the random-effects model. The fixed-effects model, using the Mantel鈥揌aenszel method, assumed that studies were sampled from populations with the same effect size, making an adjustment to the study weights according to the in-study variance. The random-effects model, using the DerSimonian and Laird method, assumed that studies were taken from populations with varying effect sizes and calculated study weights both from in-study and between-study variances, with consideration of the extent of variation or heterogeneity. We performed a X2-based Q statistic test to assess the between-study heterogeneity.24 Heterogeneity was considered significant for P 0.10 because of the low power of the statistic. The random-effects model (if P 0.10) or the fixed-effects model (if P 0.10) was used to pool the results.25 The significance of the pooled OR was determined by the Z test and a P-value of 0.05 was considered significant. For each genetic comparison, subgroup analysis according to ethnicity was considered for Asian, Caucasian and mixed African populations to estimate ethnic-specific OR. The subgroup 鈥榤ixed African鈥?included the African-American population and the Black South African population. Subgroup analysis according to different stages of hypertension was considered for stage 2 hypertension and severe hypertension. We defined the criterion of SBP猢?/span>160鈥塵m鈥塇g and/or DBP猢?/span>95鈥塵m鈥塇g as 鈥榮evere hypertension鈥?based on stage 2 hypertension, in order to expand the sample size by including the research of Kato et al.16When unexpected heterogeneity was detected, sensitivity analysis was performed to examine specific sensitivity of the findings. This was done by examining and recalculating the pooled association sizes and joint values of P in homogeneous subgroups, as well as after excluding studies one by one.Publication bias was investigated by funnel plot, in which the standard error of the log (OR) of each study was plotted against its OR. Funnel plot suggested possible publication bias, which was also assessed by Egger\'s linear regression test.26 In addition, we performed a t-test to determine the significance of the intercept, and a P-value of 0.05 was considered significant.HWE was tested by the X2-test for goodness of fit based on a web program (http://ihg.gsf.de/cgi-bin/hw/hwa1.pl). Analyses were performed using the software Stata version 7 (Stata, College Station, TX, USA) and ReviewManager 4.2. All P-values were two-sided.ResultsSelection of studiesThrough literature search and selection based on the inclusion criteria, 19 articles (23 studies) were identified by reviewing 303 articles in PubMed and 359 articles in Embase.4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 27, 28 Of the 19 eligible articles, the study of Gu et al.28 was replaced by their earlier report,10 as these two articles reported the same data. Wu et al.5 provided data on two Chinese minorities, the Hani and Yi, residents of the remote rural area of Yunnan, China.29 The population of the two minorities was also grouped in to Asian.30 Tang et al.,27 Herrmann et al.18 and Xie et al.14 provided data on two ethnicities: Caucasian American and African-American. The genotyping data of the normotensive controls in the population Caucasian-American in Tang et al.27 (PHWE=0.048), and the African-American control subjects studied in Herrmann et al.18 (PHWE=0.027) deviated from HWE. The same occurred with the data provided in Mo et al.11 (PHWE 0.001), Ge et al.10 (PHWE=0.040) and Jia et al.19 (PHWE=0.041) for the A46G polymorphism. Thus, those sub-population studies were excluded. No study of the C79G polymorphism was excluded because the data deviated from HWE. Finally, 18 articles (20 studies) were included in our analysis (Table 1). All studies used blood samples for genotyping.Summary statisticsA total of 7126 hypertension patients and 7145 controls for A46G, as well as 7346 hypertension patients and 7482 controls for C79G, were investigated. The allele frequencies were calculated for controls from the corresponding genotype distributions (Tables 2a and b). A46G allele G had a higher representation in cases and controls of Caucasians (61.2 and 62.2%, respectively) than of Asians (49.8 and 49.1%, respectively) and of the mixed African population (47.8 and 51.5%, respectively). The overall prevalence of G46 was 57.7% in cases and 59.1% in controls. C79G allele G had a much lower representation in cases and controls of Asians (6.4 and 8.1%, respectively) than of Caucasians (43.4 and 44.8%, respectively) and of the mixed African population (21.4 and 17.5%, respectively). The overall prevalence of G79 was 31.1% in cases and 35.0% in controls.Quantitative synthesisADRB2 A46GGlobal statistical results: The random-effects model was used to pool the results, as the between-study heterogeneity was significant. There was no significant association between the A46 allele and hypertension in all subjects (P=0.45, OR=1.04, 95% CI 0.94鈥?.15, Pheterogeneity 0.0001) (Figure 1a). No evidence of association was found between A46G and hypertension in the dominant genetic model (AA vs. (AG+GG)) (P=0.17, OR=1.13, 95% CI 0.95鈥?.35, Pheterogeneity=0.0002) or in the recessive genetic model ((AA+AG) vs. GG) (P=0.81, OR=0.98, 95% CI 0.87鈥?.12, Pheterogeneity=0.01). With homozygote comparison (AA vs. GG), no association could be found (P=0.43, OR=1.08, 95% CI 0.89鈥?.30, Pheterogeneity=0.002) (Table 3).Figure 1(a) Meta-analysis of the overall association between the A46G polymorphism and hypertension comparing A vs. G. n indicates the total number of A alleles; N indicates the total number of A alleles plus G alleles. (b) Meta-analysis for the association between the A46G polymorphism and hypertension comparing AA vs. AG+GG in the subgroup of mixed Africans. n indicates the total number of the AA genotype; N indicates the total number of the AA genotype plus the AG+GG genotype.Full size imageTable 3 OR (95% CI) of the association of the A46G and C79G polymorphisms and hypertension in different subgroups under various genetic contrastsFull size tableStratification analysisSignificant heterogeneity existed in five studies of Asian populations. The random-effects model was used to pool the results. No significant association was found between ADRB2 A46G and hypertension in any statistical models (Table 3). The fixed-effects model was used to pool the results of the Caucasian and the mixed African populations, as the between-study heterogeneity was insignificant. In the Caucasian population, we found no significant association between ADRB2 A46G and hypertension (Table 3). In the mixed African population, a significant association was found between the dominant genetic model (AA vs. (AG+GG)) (P=0.04, OR=1.38, 95% CI 1.01鈥?.87, Pheterogeneity=0.98) (Figure 1b), while no significant association was found in other statistic models (Table 3).No significant heterogeneity existed in three studies of stage 2 hypertension;13, 17, 27 the fixed-effects model was used to pool the results. There was no significant association between the A46 allele and stage 2 hypertension (P=0.47, OR=1.06, 95% CI 0.91鈥?.23, Pheterogeneity=0.47). No evidence of association between A46G and stage 2 hypertension in the dominant genetic model was found (AA vs. (AG+GG)) (P=0.25, OR=1.18, 95% CI 0.89鈥?.56, Pheterogeneity=0.19). The same was true for the recessive genetic model ((AA+AG) vs. GG) (P=0.89, OR=1.02, 95% CI 0.82鈥?.26, Pheterogeneity=0.68). In homozygote comparison (AA vs. GG), no association could be found (P=0.46, OR=1.13, 95% CI 0.82鈥?.54, Pheterogeneity=0.32) (Table 3).ADRB2 C79GGlobal statistical results: Significant between-study heterogeneity existed in 16 studies when we compared the C and G alleles of C79G in relation to hypertension. The random-effects model was used to pool the results. There was no significant association between the C79 allele and hypertension in all subjects (P=0.27, OR=1.06, 95% CI 0.96鈥?.18, Pheterogeneity=0.01) (Figure 2a). No evidence of association was seen between C79G and hypertension in the dominant genetic model (CC vs. (CG+GG)) (P=0.21, OR=1.10, 95% CI 0.95鈥?.27, Pheterogeneity=0.006) or in the recessive genetic model ((CC+CG) vs. GG) (P=0.43, OR=1.04, 95% CI 0.94鈥?.15, Pheterogeneity=0.90). There was no significant association in homozygote comparison (CC vs. GG) (P=0.40, OR=1.05, 95% CI 0.94鈥?.18, Pheterogeneity=0.93) (Table 3).Figure 2(a) Meta-analysis of the overall association between the C79G polymorphism and hypertension comparing C vs. G. n indicates the total number of C alleles; N indicates the total number of C alleles plus G alleles. (b) Meta-analysis for the association between the C79G polymorphism and systolic blood pressure (SBP)猢?/span>160鈥塵m鈥塇g and/or diastolic blood pressure (DBP)猢?/span>95鈥塵m鈥塇g hypertension comparing CC vs. CG+GG. n indicates the total number of the CC genotype; N indicates the total number of the CC genotype plus the CG+GG genotype. (c) Meta-analysis for the association between the C79G polymorphism and SBP猢?/span>160鈥塵m鈥塇g and/or DBP猢?/span>95鈥塵m鈥塇g hypertension comparing C vs. G. n indicates the total number of C alleles; N indicates the total number of C alleles plus G alleles.Full size imageStratification analysisSignificant heterogeneity existed in six studies of Asians; the random-effects model was used for allele comparison, and no significant association was found (Table 3). There was also no significant association found in other genetic models conducted using Asians (Table 3). The fixed-effects model was used to pool the results for the Caucasian and mixed African populations, as the between-study heterogeneity was insignificant. There was no significant association with hypertension found in either population (Table 3).Meta-analysis in the subgroup of stage 2 hypertension could not find significant association with the C79G polymorphism in the three studies included.10, 13, 17 No association was found between the C79 allele and stage 2 hypertension (P=0.11, OR=1.30, 95% CI 0.94鈥?.81, Pheterogeneity=0.01, random-effects model), in the dominant genetic model (CC vs. (CG+GG)) (P=0.09, OR=1.47, 95% CI 0.94鈥?.30, Pheterogeneity=0.02, random-effects model), in the recessive genetic model ((CC+CG) vs. GG) (P=0.75, OR=1.05, 95% CI 0.80鈥?.37, Pheterogeneity=0.55, fixed-effects model), or in the homozygote comparison (CC vs. GG) (P=0.57, OR=1.10, 95% CI 0.79鈥?.53, Pheterogeneity=0.74, fixed-effects model).To uncover the potential association between C79G polymorphisms and hypertension, further research was conducted on severe hypertension (SBP猢?/span>160鈥塵m鈥塇g and/or DBP猢?/span>95鈥塵m鈥塇g hypertensive population); four studies were included10, 13, 16, 17 (Table 4). Significant association was found in the dominant genetic model (CC vs. (CG+GG)) (P=0.04, OR=1.38, 95% CI 1.02鈥?.86, Pheterogeneity=0.03, random-effects model) (Figure 2b), and there was also a borderline significance between the C79 allele and hypertension (P=0.05, OR=1.26, 95% CI 1.00鈥?.57, Pheterogeneity=0.04, random-effects model) (Figure 2c), whereas no association was found in the recessive genetic model ((CC+CG) vs. GG) (P=0.77, OR=1.04, 95% CI 0.80鈥?.36, Pheterogeneity=0.75, fixed-effects model) or in homozygote comparison (CC vs. GG) (P=0.59, OR=1.09, 95% CI 0.79鈥?.50, Pheterogeneity=0.89, fixed-effects model).Table 4 Comparison of characteristics between cases and controls in the articles studied the association between 鈥榮evere hypertension鈥?and ADRB2 C79G polymorphismFull size tableSensitivity analysisBetween-study heterogeneity existed in all the studies using Asian subjects, but not in those using Caucasians and mixed African populations. Sensitivity analysis was conducted by sequential omission of individual studies overall and of Asians. As such, the Wu et al.5 article on the Yi Chinese minority was excluded; it appeared that the overall between-study heterogeneity no longer existed for the A46G polymorphism and no association could be found (A vs. G, P=0.61, OR=1.01, 95% CI 0.96鈥?.06, Pheterogeneity=0.22, fixed-effects model). A similar result was found in the study of Ge et al.10 on the Han Chinese and prevalence of the C79G, which was also excluded; it appeared there was no association found overall (C vs. G, P=0.29, OR=1.03, 95% CI 0.98鈥?.09, Pheterogeneity=0.18, fixed-effects model). However, in the Asian population, between-study heterogeneity still existed when any single study was excluded.Publication biasThe funnel plot was applied for comparison of A46 vs. G46 in the OR analysis of ADRB2 A46G, and Egger\'s test provided no evidence for funnel-plot asymmetry (t=鈭?.17, P=0.868; Figure 3a). Similarly, no publication bias was detected for the C79G polymorphism (t=鈭?.21, P=0.838; Figure 3b).Figure 3(a) Funnel plot for A vs. G allele comparison of the A46G polymorphism. (b) Funnel plot for C vs. G allele comparison of the C79G polymorphism.Full size imageDiscussionWe performed a systematic review of the literature by means of a meta-analysis on the association between the ADRB2 A46G and C79G polymorphisms and essential hypertension, without evidence of publication bias for the outcome. To avoid reporting bias, we contacted the authors for raw data. We acquired the data, including 6495 Caucasian subjects from Gjesing et al.,20 but failed to gain information from two original studies31, 32 of Asians, which included 1700 subjects altogether. These two papers both indicated 鈥榥egative鈥?results of A46G and C79G polymorphisms, which were consistent with our results of meta-analysis in Asians and overall.Sensitivity analysis revealed that when two studies on Chinese subjects5, 10 were excluded, significant overall heterogeneity did not exist. The source of heterogeneity might be attributed to two factors. The first is the genetic difference in the sub-ethnic groups of the Chinese population. In the Wu et al. study,5 the ethnic minorities Yi and Hani were recruited for the analysis but not the Han ethnic majority. The genetic differences between these populations should not be neglected.30 Even in Han Chinese, a recent genome-wide association study suggested that certain genetic characteristics of the Han population correlated with geographical locations.33 The genetic difference made it such that heterogeneity in the meta-analysis was inevitable. Another source of heterogeneity might be related to the quality of the studies, such as small samples and different inclusion criteria. Multicenter genome-wide association study with larger samples might help to elucidate the association between hundreds of thousands of locus variants and hypertension, which would minimize the heterogeneity of samples and would also examine the loci rarely studied by traditional single-nucleotide polymorphism genotyping technology. However, despite our best efforts, we have not found any genome-wide association study of this locus published.In the meta-analysis of the association between the ADRB2 C79G polymorphism and hypertension, our results showed no overall association or an ethnicity-specific association. Similar results were found for the stage 2 hypertension population. Interestingly, the meta-analysis on 鈥榮evere hypertension鈥?showed significant association between C79G and hypertension in the dominant genetic model (CC vs. (CG+GG)), as well as in the comparison of the C and G alleles. We were curious to understand why an association occurred for particular criterion in the hypertensive population, but not in the population as a whole or in the subgroups of stage 2 hypertensives. Few studies (only three articles10, 13, 17) investigated the correlation between this polymorphism and stage 2 hypertension. When we defined 鈥榮evere hypertension鈥? the sample size expanded by more than 80%; by including the research of Kato et al.,16 significant association could be found. To avoid overestimation by possible bias of other factors, we analyzed the detailed information of these four studies. Kato et al.\'s study, involving both non-diabetic and diabetic patients (Table 4), deviated from the other three studies. To avoid potential bias because of diabetes, we excluded the diabetic subjects (294 hypertensive patients and 213 normotensive controls) and recalculated the pooled results. Significant association was stable in both models (CC vs. (CG+GG), P=0.01, OR=1.44, 95% CI 1.07鈥?.93, Pheterogeneity=0.05, random-effects model; C vs. G, P=0.03, OR=1.30, 95% CI 1.03鈥?.66, Pheterogeneity=0.03, random-effects model).Cockcroft et al.34 studied the regulation of the 尾2-adrenoceptor on vessel resistance. The results indicate that homozygotes for A46 had significantly lower basal blood flow and attenuated increases in forearm blood flow compared with the G46 homozygotes, which could be explained by the variability in vascular responsiveness to isoproterenol in the vascular bed associated with A46G polymorphism.35 Lang et al.36 and Johnson et al.37 provided a schematic diagram to explain the functional difference of vascular responsiveness in Africans and Caucasians. In Africans, the degree of vasodilatation and chronotropic effects in response to isoproterenol in the forearm was markedly higher than that of Caucasians, whereas baseline blood flow was similar in the two populations. In our meta-analysis, we demonstrated association of A46G polymorphisms with essential hypertension in the subgroup of the mixed African population, but not in Caucasians. The frequency of A46 homozygotes in the mixed African population was considerably higher in hypertensives than in normotensives, whereas no association could be found in other ethnicities. This suggests that the mechanisms responsible for blunted vasodilatation mediated by 尾2-adrenoceptors in response to the administration of isoproterenol might contribute to enhanced vascular reactivity in Africans and might have a role in the pathogenesis of hypertension in Africans.Some studies have reported that in G79 subjects, locally applied isoprenaline caused larger increases in forearm blood flow34 and dilation of hand veins34, 35 than in C79 subjects. In other words, A46G polymorphisms and C79G polymorphisms seem to share similar mechanisms in conducting blood flow in resistance vessels. This is very likely due to the linkage disequilibrium between A46G and C79G.38, 39, 40 Owing to linkage disequilibrium, subjects homozygous for G79 are nearly always homozygous for G46, whereas naturally occurring A46/G79 is rare.41, 42, 43 Pojoga et al.6 observed that AA46/CC79 was significantly associated with higher blood pressure, which might be attributed to the enhancement of the AA46/CC79 diplotype.In conclusion, our meta-analysis suggests significant association between the ADRB2 A46G polymorphism and hypertension in the mixed African population. The ADRB2 C79G polymorphism had significant association with an SBP猢?/span>160鈥塵m鈥塇g and/or DBP猢?/span>95鈥塵m鈥塇g in the hypertensive population. The role of both polymorphisms might contribute to enhanced vascular reactivity to isoproterenol in capacitance vessels.34 More studies or large case鈥揷ontrol studies, and especially studies stratified for different ethnicities and different stages of hypertension, should be performed to clarify the association between ADRB2 polymorphisms and essential hypertension. Studies on the pathophysiologic mechanisms of the possible roles of A46G and C79G in hypertension are important as well. References1O鈥橲haughnessy KM . The genetics of essential hypertension. Br J Clin Pharmacol 2001; 51: 5鈥?1.Article聽Google Scholar聽 2Kobilka BK, Dixon RA, Frielle T, Dohlman HG, Bolanowski MA, Sigal IS, Yang-Feng TL, Francke U, Caron MG, Lefkowitz RJ . cDNA for the human 尾2-adrenergic receptor: a protein with multiple membrane spanning domains and encoded by a gene whose chromosomal location is shared with that of the receptor for platelet-derived growth factor. Proc Natl Acad Sci USA 1987; 84: 46鈥?0.CAS聽 Article聽Google Scholar聽 3Green SA, Turki J, Innis M, Liggett SB . Amino-terminal polymorphisms of the human beta 2-adrenergic receptor impart distinct agonist-promoted regulatory properties. Biochemistry 1994; 33: 9414鈥?419.CAS聽 Article聽Google Scholar聽 4Filigheddu F, Reid JE, Troffa C, PinnaParpaglia P, Argiolas G, Testa A, Skolnick M, Glorioso N . Genetic polymorphisms of the beta-adrenergic system: association with essential hypertension and response to beta-blockade. Pharmacogenomics J 2004; 4: 154鈥?60.CAS聽 Article聽Google Scholar聽 5Wu H, Tang W, Li H, Zhou X, Yang Y, Yu H, Li K, Xiao C, Deng AY . Association of the beta2-adrenergic receptor gene with essential hypertension in the non-Han Chinese Yi minority human population. J Hypertens 2006; 24: 1041鈥?047.CAS聽 Article聽Google Scholar聽 6Pojoga L, Kolatkar NS, Williams JS, Perlstein TS, Jeunemaitre X, Brown NJ, Hopkins PN, Raby BA, Williams GH . Beta-2 adrenergic receptor diplotype defines a subset of salt-sensitive hypertension. Hypertension 2006; 48: 892鈥?00.CAS聽 Article聽Google Scholar聽 7Misono M, Maeda S, Iemitsu M, Nakata Y, Otsuki T, Sugawara J, Zempo H, Yoshizawa M, Miyaki A, Kuno S, Matsuda M, Ajisaka R . Combination of polymorphisms in the beta2-adrenergic receptor and nitric oxide synthase 3 genes increases the risk for hypertension. J Hypertens 2009; 27: 1377鈥?383.CAS聽 Article聽Google Scholar聽 8Castellano M, Rossi F, Giacch猫 M, Perani C, Rivadossi F, Muiesan ML, Salvetti M, Beschi M, Rizzoni D, Agabiti-Rosei E . Beta(2)-adrenergic receptor gene polymorphism, age, and cardiovascular phenotypes. Hypertension 2003; 41: 361鈥?67.CAS聽 Article聽Google Scholar聽 9Yu SF, Zhou WH, Jiang KY, Gu GZ, Wang S . Job stress, gene polymorphism of beta2-AR, and prevalence of hypertension. Biomed Environ Sci 2008; 21: 239鈥?46.CAS聽 Article聽Google Scholar聽 10Ge D, Huang J, He J, Li B, Duan X, Chen R, Gu D . Beta2-adrenergic receptor gene variations associated with stage-2 hypertension in northern Han Chinese. Ann Hum Genet 2005; 69: 36鈥?4.CAS聽 Article聽Google Scholar聽 11Mo W, Zhang GG, Yang TL, Dai XP, Li HH, Zeng H, Liu J, Tan YM, Zhou HH, Liu ZQ . The genetic polymorphisms of beta3-adrenergic receptor (AR) Trp64Arg and beta2-AR Gln27Glu are associated with obesity in Chinese male hypertensive patients. Clin Chem Lab Med 2007; 45: 493鈥?98.CAS聽 Article聽Google Scholar聽 12Candy G, Samani N, Norton G, Woodiwiss A, Radevski I, Wheatley A, Cockcroft J, Hall IP . Association analysis of beta2 adrenoceptor polymorphisms with hypertension in a Black African population. J Hypertens 2000; 18: 167鈥?72.CAS聽 Article聽Google Scholar聽 13Sunder-Plassmann G, Kittler H, Eberle C, Hirschl MM, Woisetschl盲ger C, Derhaschnig U, Laggner AN, H枚rl WH, F枚dinger M . Angiotensin converting enzyme DD genotype is associated with hypertensive crisis. Crit Care Med 2002; 30: 2236鈥?241.CAS聽 Article聽Google Scholar聽 14Xie HG, Stein CM, Kim RB, Gainer JV, Sofowora G, Dishy V, Brown NJ, Goree RE, Haines JL, Wood AJ . Human beta2-adrenergic receptor polymorphisms: no association with essential hypertension in black or white Americans. Clin Pharmacol Ther 2000; 67: 670鈥?75.CAS聽 Article聽Google Scholar聽 15Bartels NK, B枚rgel J, Wieczorek S, B眉chner N, Hanefeld C, Bulut D, M眉gge A, Rump LC, Sanner BM, Epplen JT . Risk factors and myocardial infarction in patients with obstructive sleep apnea: impact of beta2-adrenergic receptor polymorphisms. BMC Med 2007; 5: 1.Article聽Google Scholar聽 16Kato N, Sugiyama T, Morita H, Kurihara H, Sato T, Yamori Y, Yazaki Y . Association analysis of beta(2)-adrenergic receptor polymorphisms with hypertension in Japanese. Hypertension 2001; 37: 286鈥?92.CAS聽 Article聽Google Scholar聽 17Herrmann SM, Nicaud V, Tiret L, Evans A, Kee F, Ruidavets JB, Arveiler D, Luc G, Morrison C, Hoehe MR, Paul M, Cambien F . Polymorphisms of the beta2 -adrenoceptor (ADRB2) gene and essential hypertension: the ECTIM and PEGASE studies. J Hypertens 2002; 20: 229鈥?35.CAS聽 Article聽Google Scholar聽 18Herrmann V, B眉scher R, Go MM, Ring KM, Hofer JK, Kailasam MT, O鈥機onnor DT, Parmer RJ, Insel PA . Beta2-adrenergic receptor polymorphisms at codon 16, cardiovascular phenotypes and essential hypertension in whites and African Americans. Am J Hypertens 2000; 13: 1021鈥?026.CAS聽 Article聽Google Scholar聽 19Jia H, Sharma P, Hopper R, Dickerson C, Lloyd DD, Brown MJ . beta2-adrenoceptor gene polymorphisms and blood pressure variations in East Anglian Caucasians. J Hypertens 2000; 18: 687鈥?93.CAS聽 Article聽Google Scholar聽 20Gjesing AP, Andersen G, Burgdorf KS, Borch-Johnsen K, J酶rgensen T, Hansen T, Pedersen O . Studies of the associations between functional beta2-adrenergic receptor variants and obesity, hypertension and type 2 diabetes in 7808 white subjects. Diabetologia 2007; 50: 563鈥?68.CAS聽 Article聽Google Scholar聽 21Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, Grassi G, Heagerty AM, Kjeldsen SE, Laurent S, Narkiewicz K, Ruilope L, Rynkiewicz A, Schmieder RE, Boudier HA, Zanchetti A, Vahanian A, Camm J, De Caterina R, Dean V, Dickstein K, Filippatos G, Funck-Brentano C, Hellemans I, Kristensen SD, McGregor K, Sechtem U, Silber S, Tendera M, Widimsky P, Zamorano JL, Erdine S, Kiowski W, Agabiti-Rosei E, Ambrosioni E, Lindholm LH, Viigimaa M, Adamopoulos S, Agabiti-Rosei E, Ambrosioni E, Bertomeu V, Clement D, Erdine S, Farsang C, Gaita D, Lip G, Mallion JM, Manolis AJ, Nilsson PM, O鈥橞rien E, Ponikowski P, Redon J, Ruschitzka F, Tamargo J, van Zwieten P, Waeber B, Williams B . 2007 Guidelines for the Management of Arterial Hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007; 25: 1105鈥?187.CAS聽 Article聽Google Scholar聽 22Ogihara T, Kikuchi K, Matsuoka H, Fujita T, Higaki J, Horiuchi M, Imai Y, Imaizumi T, Ito S, Iwao H, Kario K, Kawano Y, Kim-Mitsuyama S, Kimura G, Matsubara H, Matsuura H, Naruse M, Saito I, Shimada K, Shimamoto K, Suzuki H, Takishita S, Tanahashi N, Tsuchihashi T, Uchiyama M, Ueda S, Ueshima H, Umemura S, Ishimitsu T, Rakugi H . The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2009). Hypertens Res 2009; 32: 3鈥?07.CAS聽Google Scholar聽 23Woolf B . On estimating the relation between blood group and disease. Ann Hum Genet 1955; 19: 251鈥?53.CAS聽 Article聽Google Scholar聽 24Lau J, Ioannidis JP, Schmid CH . Quantitative synthesis in systematic reviews. Ann Intern Med 1997; 127: 820鈥?26.CAS聽 Article聽Google Scholar聽 25Petitti D . Meta-analysis, Decision Analysis, and Cost-effectiveness Analysis. Oxford University Press: New York, 1994. Google Scholar聽 26Egger M, Davey Smith G, Schneider M, Minder C . Bias in meta-analysis detected by a simple, graphical test. Br Med J 1997; 315: 629鈥?34.CAS聽 Article聽Google Scholar聽 27Tang W, Devereux RB, Kitzman DW, Province MA, Leppert M, Oberman A, Hopkins PN, Arnett DK . The Arg16Gly polymorphism of the beta2-adrenergic receptor and left ventricular systolic function. Am J Hypertens 2003; 16: 945鈥?51.CAS聽 Article聽Google Scholar聽 28Gu D, Su S, Ge D, Chen S, Huang J, Li B, Chen R, Qiang B . Association study with 33 single-nucleotide polymorphisms in 11 candidate genes for hypertension in Chinese. Hypertension 2006; 47: 1147鈥?154.CAS聽 Article聽Google Scholar聽 29Tang W, Wu H, Zhou X, Cheng B, Dong Y, He L, Yu H, Xu L, Lu J, Li K, Xiao C . Association of the C-344T polymorphism of CYP11B2 gene with essential hypertension in Hani and Yi minorities of China. Clin Chim Acta 2006; 364: 222鈥?25.CAS聽 Article聽Google Scholar聽 30Deng W, Shi B, He X, Zhang Z, Xu J, Li B, Yang J, Ling L, Dai C, Qiang B, Shen Y, Chen R . Evolution and migration history of the Chinese population inferred from Chinese Y-chromosome evidence. J Hum Genet 2004; 49: 339鈥?48.Article聽Google Scholar聽 31Hu CJ, Wang CH, Lee JH, Hsieh CM, Cheng CC, Chang SC, Chang CJ . Association between polymorphisms of ACE, B2AR, ANP and ENOS and cardiovascular diseases: a community-based study in the Matsu area. Clin Chem Lab Med 2007; 45: 20鈥?5.CAS聽 Article聽Google Scholar聽 32Lee YW, Oh VM, Garcia E, Taylor EA, Wu H, Yap EP, Kazeem GR, Caulfield MJ, Munroe PB . Haplotypes of the beta2-adrenergic receptor gene are associated with essential hypertension in a Singaporean Chinese population. J Hypertens 2004; 22: 2111鈥?116.CAS聽 Article聽Google Scholar聽 33Xu S, Yin X, Li S, Jin W, Lou H, Yang L, Gong X, Wang H, Shen Y, Pan X, He Y, Yang Y, Wang Y, Fu W, An Y, Wang J, Tan J, Qian J, Chen X, Zhang X, Sun Y, Zhang X, Wu B, Jin L . Genomic dissection of population substructure of Han Chinese and its implication in association studies. Am J Hum Genet 2009; 85: 762鈥?74.CAS聽 Article聽Google Scholar聽 34Cockcroft JR, Gazis AG, Cross DJ, Wheatley A, Dewar J, Hall IP, Noon JP . 2-Adrenoceptor polymorphism determines vascular reactivity in humans. Hypertension 2000; 36: 371鈥?75.CAS聽 Article聽Google Scholar聽 35Dishy V, Sofowora GG, Xie HG, Kim RB, Byrne DW, Stein CM, Wood AJ . The effect of common polymorphisms of the beta2-adrenergic receptor on agonist-mediated vascular desensitization. N Engl J Med 2001; 345: 1030鈥?035.CAS聽 Article聽Google Scholar聽 36Lang CC, Stein CM, Brown RM, Deegan R, Nelson R, He HB, Wood M, Wood AJ . Attenuation of isoproterenol-mediated vasodilatation in blacks. N Engl J Med 1995; 333: 155鈥?60.CAS聽 Article聽Google Scholar聽 37Johnson JA, Burlew BS, Stiles RN . Racial differences in beta-adrenoceptor-mediated responsiveness. J Cardiovasc Pharmacol 1995; 25: 90鈥?6.CAS聽 Article聽Google Scholar聽 38McGraw DW, Forbes SL, Kramer LA, Liggett SB . Polymorphisms of the 5鈥?leader cistron of the human beta2-adrenergic receptor regulate receptor expression. J Clin Invest 1998; 102: 1927鈥?932.CAS聽 Article聽Google Scholar聽 39Drysdale CM, McGraw DW, Stack CB, Stephens JC, Judson RS, Nandabalan K, Arnold K, Ruano G, Liggett SB . Complex promoter and coding region beta 2-adrenergic receptor haplotypes alter receptor expression and predict in vivo responsiveness. Proc Natl Acad Sci USA 2000; 97: 10483鈥?0488.CAS聽 Article聽Google Scholar聽 40Belfer I, Buzas B, Evans C, Hipp H, Phillips G, Taubman J, Lorincz I, Lipsky RH, Enoch MA, Max MB, Goldman D . Haplotype structure of the beta adrenergic receptor genes in US Caucasians and African Americans. Eur J Hum Genet 2005; 13: 341鈥?51.CAS聽 Article聽Google Scholar聽 41Small KM, McGraw DW, Liggett SB . Pharmacology and physiology of human adrenergic receptor polymorphisms. Annu Rev Pharmacol Toxicol 2003; 43: 381鈥?11.CAS聽 Article聽Google Scholar聽 42Kirstein SL, Insel PA . Autonomic nervous system pharmacogenomics: a progress report. Pharmacol Rev 2004; 56: 31鈥?2.CAS聽 Article聽Google Scholar聽 43Leineweber K, B眉scher R, Bruck H, Brodde OE . Beta-adrenoceptor polymorphisms. Naunyn Schmiedebergs Arch Pharmacol 2004; 369: 1鈥?2.CAS聽 Article聽Google Scholar聽 Download referencesAcknowledgementsThis work was funded by grants 2008AA02Z441 of the National High Technology Research and Development Program, and grants 2008BAI52B03 of the National Eleventh Five-year Plan Program from the Ministry of Science and Technology of the People鈥檚 Republic of China.Author informationAuthor notesYuqing Lou and Jinghua Liu: These authors contributed equally to this work.Shaojun Wen: Member of International Society of Hypertension.AffiliationsDepartment of Hypertension Research, Beijing Anzhen Hospital, Capital Medical University and Beijing Institute of Heart Lung and Blood Vessel Diseases, Beijing, PR ChinaYuqing Lou,聽Jielin Liu,聽Zuoguang Wang,聽Ya Liu聽 聽Shaojun WenDepartment of Cardiology, Beijing Anzhen Hospital, Capital Medical University, Beijing, PR ChinaJinghua Liu聽 聽Zhizhong LiState Key Laboratory of Genetic Engineering, Institute of Genetics, School of Life Sciences, Fudan University, Shanghai, PR ChinaYan Huang,聽Yao Li聽 聽Yi XieAuthorsYuqing LouView author publicationsYou can also search for this author in PubMed聽Google ScholarJinghua LiuView author publicationsYou can also search for this author in PubMed聽Google ScholarYan HuangView author publicationsYou can also search for this author in PubMed聽Google ScholarJielin LiuView author publicationsYou can also search for this author in PubMed聽Google ScholarZuoguang WangView author publicationsYou can also search for this author in PubMed聽Google ScholarYa LiuView author publicationsYou can also search for this author in PubMed聽Google ScholarZhizhong LiView author publicationsYou can also search for this author in PubMed聽Google ScholarYao LiView author publicationsYou can also search for this author in PubMed聽Google ScholarYi XieView author publicationsYou can also search for this author in PubMed聽Google ScholarShaojun WenView author publicationsYou can also search for this author in PubMed聽Google ScholarCorresponding authorsCorrespondence to Yi Xie or Shaojun Wen.Ethics declarations Competing interests The authors declare no conflict of interest. Rights and permissionsReprints and PermissionsAbout this articleCite this articleLou, Y., Liu, J., Huang, Y. et al. A46G and C79G polymorphisms in the 尾2-adrenergic receptor gene (ADRB2) and essential hypertension risk: a meta-analysis. Hypertens Res 33, 1114鈥?123 (2010). https://doi.org/10.1038/hr.2010.151Download citationReceived: 09 February 2010Revised: 12 May 2010Accepted: 01 June 2010Published: 26 August 2010Issue Date: November 2010DOI: https://doi.org/10.1038/hr.2010.151Keywordsadrenergic receptormeta-analysispolymorphism Amit Kumar, Manjari Tripathi, Madakasira Vasantha Padma Srivastava, Subbiah Vivekanandhan Kameshwar Prasad BMC Research Notes (2014) Fumihiko Takeuchi, Ken Yamamoto, Tomohiro Katsuya, Takao Sugiyama, Toru Nabika, Keizo Ohnaka, Shuhei Yamaguchi, Ryoichi Takayanagi, Toshio Ogihara Norihiro Kato Hypertension Research (2012)